RU2019120956A - Способы лечения воспалительных состояний легких - Google Patents
Способы лечения воспалительных состояний легких Download PDFInfo
- Publication number
- RU2019120956A RU2019120956A RU2019120956A RU2019120956A RU2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A
- Authority
- RU
- Russia
- Prior art keywords
- defensin
- asthma
- day
- subject
- peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 29
- 230000002757 inflammatory effect Effects 0.000 title claims 2
- 230000002685 pulmonary effect Effects 0.000 title 1
- 102000000541 Defensins Human genes 0.000 claims 16
- 108010002069 Defensins Proteins 0.000 claims 16
- 208000006673 asthma Diseases 0.000 claims 12
- 210000004072 lung Anatomy 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 241000736262 Microbiota Species 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 102100038326 Beta-defensin 4A Human genes 0.000 claims 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims 2
- 108050004676 Histone deacetylase 5 Proteins 0.000 claims 2
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- -1 truncated hBD2 Proteins 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 102100037437 Beta-defensin 1 Human genes 0.000 claims 1
- 102100026887 Beta-defensin 103 Human genes 0.000 claims 1
- 102100026886 Beta-defensin 104 Human genes 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 206010050685 Cytokine storm Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 1
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims 1
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 claims 1
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims 1
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 claims 1
- 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 claims 1
- 101000929203 Homo sapiens Neutrophil defensin 4 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 101800004361 Lactoferricin-B Proteins 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 102000016943 Muramidase Human genes 0.000 claims 1
- 108010014251 Muramidase Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101800000287 Neutrophil defensin 2 Proteins 0.000 claims 1
- 102100024761 Neutrophil defensin 3 Human genes 0.000 claims 1
- 102100036348 Neutrophil defensin 4 Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108060001132 cathelicidin Proteins 0.000 claims 1
- 102000014509 cathelicidin Human genes 0.000 claims 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010052015 cytokine release syndrome Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 102000018475 human neutrophil peptide 2 Human genes 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000024710 intermittent asthma Diseases 0.000 claims 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 1
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- 229940078795 lactoferrin Drugs 0.000 claims 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 235000010335 lysozyme Nutrition 0.000 claims 1
- 229960000274 lysozyme Drugs 0.000 claims 1
- 239000004325 lysozyme Substances 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- GRZXCHIIZXMEPJ-HTLKCAKFSA-N neutrophil peptide-2 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@@H](N)CSSC[C@H](NC2=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 GRZXCHIIZXMEPJ-HTLKCAKFSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 1
- 229960003040 rifaximin Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670991 | 2016-12-13 | ||
| DKPA201670991 | 2016-12-13 | ||
| PCT/EP2017/082535 WO2018108971A2 (en) | 2016-12-13 | 2017-12-13 | Methods for treating inflammatory conditions of the lungs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019120956A true RU2019120956A (ru) | 2021-01-15 |
| RU2019120956A3 RU2019120956A3 (https=) | 2021-04-13 |
Family
ID=61024712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120956A RU2019120956A (ru) | 2016-12-13 | 2017-12-13 | Способы лечения воспалительных состояний легких |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11413328B2 (https=) |
| EP (1) | EP3554532B1 (https=) |
| JP (2) | JP2020512287A (https=) |
| KR (1) | KR20190108106A (https=) |
| CN (1) | CN110290799A (https=) |
| AU (1) | AU2017376400A1 (https=) |
| BR (1) | BR112019011844A2 (https=) |
| CA (1) | CA3045079A1 (https=) |
| ES (1) | ES2994381T3 (https=) |
| MX (1) | MX2019006848A (https=) |
| RU (1) | RU2019120956A (https=) |
| SG (1) | SG10202012106WA (https=) |
| WO (1) | WO2018108971A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020004863A (es) * | 2017-11-10 | 2020-10-14 | Defensin Therapeutics Aps | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. |
| CN108815199B (zh) * | 2018-08-03 | 2021-10-01 | 南华大学 | 鼠衣原体在制备抗溃疡性结肠炎药物中的应用 |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| CN113164390A (zh) | 2018-10-09 | 2021-07-23 | 达特·特兰 | 用于增强阳离子大环肽的全身递送能力、耐受性和效力的组合物和方法 |
| JP7479381B2 (ja) * | 2019-01-07 | 2024-05-08 | アエスクルス バイオ エーピーエス | 治療または予防に使用するためのディフェンシン断片 |
| CA3132564A1 (en) * | 2019-03-14 | 2020-09-17 | Om Pharma Sa | Process for making stable bacterial extracts and their use as pharmaceuticals |
| US12472231B2 (en) | 2020-03-18 | 2025-11-18 | The University Of Hong Kong | Compositions of anti-viral peptides and methods of use thereof |
| CN113262297A (zh) * | 2020-11-02 | 2021-08-17 | 中南大学湘雅二医院 | 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用 |
| CN113521047B (zh) * | 2021-08-23 | 2022-10-04 | 新疆医科大学第四附属医院 | 丁酸盐在制备慢性阻塞性肺疾病药物中的应用 |
| CN118451094A (zh) * | 2021-12-27 | 2024-08-06 | 港大科桥有限公司 | 抗病毒肽及其使用方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2003070176A2 (en) | 2002-02-19 | 2003-08-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Modified defensins and their use |
| CA2487895A1 (en) | 2002-05-31 | 2003-12-11 | Ciphergen Biosystems, Inc. | Defensins: use as antiviral agents |
| GB0521139D0 (en) * | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| US7528107B2 (en) | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2008115390A2 (en) | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| AP2011005537A0 (en) * | 2008-07-18 | 2011-02-28 | Novozymes Adenium Biotech As | Treatment of inflammatory diseases with mammal beta defensins. |
| SG172709A1 (en) | 2008-07-18 | 2011-07-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| US8828380B2 (en) * | 2009-09-10 | 2014-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the treatment of pulmonary disease and method of producing proteins of use therein |
| US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| KR101329774B1 (ko) | 2010-06-16 | 2013-11-15 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| US20130281361A1 (en) * | 2010-11-08 | 2013-10-24 | Pulmatrix, Inc. | Methods of treating and preventing rhinovirus infection |
| JP6219277B2 (ja) | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| US20130052213A1 (en) * | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| US9464124B2 (en) * | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2653754C2 (ru) | 2012-12-06 | 2018-05-14 | Пин Фарма, Инк. | Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат |
| MX2020004863A (es) | 2017-11-10 | 2020-10-14 | Defensin Therapeutics Aps | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. |
-
2017
- 2017-12-13 MX MX2019006848A patent/MX2019006848A/es unknown
- 2017-12-13 BR BR112019011844A patent/BR112019011844A2/pt not_active Application Discontinuation
- 2017-12-13 CN CN201780086292.7A patent/CN110290799A/zh active Pending
- 2017-12-13 RU RU2019120956A patent/RU2019120956A/ru unknown
- 2017-12-13 WO PCT/EP2017/082535 patent/WO2018108971A2/en not_active Ceased
- 2017-12-13 EP EP17835461.9A patent/EP3554532B1/en active Active
- 2017-12-13 CA CA3045079A patent/CA3045079A1/en active Pending
- 2017-12-13 US US16/468,051 patent/US11413328B2/en active Active
- 2017-12-13 JP JP2019531167A patent/JP2020512287A/ja not_active Ceased
- 2017-12-13 ES ES17835461T patent/ES2994381T3/es active Active
- 2017-12-13 AU AU2017376400A patent/AU2017376400A1/en active Pending
- 2017-12-13 KR KR1020197019175A patent/KR20190108106A/ko not_active Ceased
- 2017-12-13 SG SG10202012106WA patent/SG10202012106WA/en unknown
-
2022
- 2022-07-11 US US17/861,912 patent/US20230067261A1/en not_active Abandoned
-
2024
- 2024-10-22 JP JP2024186110A patent/JP2025013922A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017376400A1 (en) | 2019-06-20 |
| WO2018108971A3 (en) | 2018-07-26 |
| BR112019011844A2 (pt) | 2022-05-10 |
| KR20190108106A (ko) | 2019-09-23 |
| US20190336576A1 (en) | 2019-11-07 |
| CN110290799A (zh) | 2019-09-27 |
| EP3554532A2 (en) | 2019-10-23 |
| US20230067261A1 (en) | 2023-03-02 |
| JP2020512287A (ja) | 2020-04-23 |
| ES2994381T3 (en) | 2025-01-23 |
| EP3554532C0 (en) | 2024-09-25 |
| EP3554532B1 (en) | 2024-09-25 |
| SG10202012106WA (en) | 2021-01-28 |
| JP2025013922A (ja) | 2025-01-28 |
| CA3045079A1 (en) | 2018-06-21 |
| MX2019006848A (es) | 2019-10-07 |
| WO2018108971A2 (en) | 2018-06-21 |
| RU2019120956A3 (https=) | 2021-04-13 |
| US11413328B2 (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019120956A (ru) | Способы лечения воспалительных состояний легких | |
| US20080167230A1 (en) | Methods and compositions for treating or preventing lesions of the respiratory epithelium | |
| US20090227511A1 (en) | Methods and compositions for treating lesions of the respiratory epithelium | |
| EP2421901B1 (en) | Compositions containing hc ha complex and methods of use thereof | |
| US9833495B2 (en) | Oral treatment of inflammatory bowel disease | |
| JP2013504545A (ja) | Ｃｘｃｌ８媒介肺炎症の治療のための組成物 | |
| SG174892A1 (en) | Use of andrographolide compounds for treating inflammation and airway disorders | |
| WO2019048660A1 (en) | MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY | |
| JP2021502363A5 (https=) | ||
| US11453880B2 (en) | Chimeric decoy | |
| WO2023203586A1 (en) | Inhalable pharmaceutical composition comprising the protein anakinra for the treatment of inflammation in cystic fibrosis | |
| Ye et al. | Pulmonary C-fiber degeneration downregulates IFN-γ receptor 1 via IFN-α induction to attenuate RSV-induced airway hyperresponsiveness | |
| JP2021504348A5 (https=) | ||
| CN117209612A (zh) | 融合蛋白及其应用 | |
| CN101437849B (zh) | 胰岛素衍生物 | |
| US8455437B2 (en) | Method to predict and prevent oxygen-induced inflammatory tissue injury | |
| US20240325383A1 (en) | Small Molecule Targeting of BRD4 for Treatment of COVID-19 | |
| Nishimoto et al. | Targeting TNF-α signaling pathway with ligand-specific antibody reverses corticosteroid insensitivity and/or airway inflammation in mice | |
| Lee et al. | Korean Red Ginseng and Saponin Regulate the Cytokine and Mucin 5AC/5B Induced by Electronic Cigarette in Respiratory Epithelial Cell | |
| WO2024077042A2 (en) | Il-1 receptor antagonist treatment for neutrophilic lung disease | |
| Alenzi et al. | The role of eosinophils in asthma | |
| WO2009091645A2 (en) | Compositions and methods for treating chondrosarcomas | |
| WO2010135459A2 (en) | Brain delivery of insulin to treat systemic inflammation | |
| YAN et al. | Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma | |
| Rymut et al. | C60 ALL ABOUT CYSTIC FIBROSIS: High-Dose Ibuprofen Dampens Inflammatory Signaling Via Microtubule Structure And Dynamics In Cystic Fibrosis Epithelial Cells |